Overview
Given the biotechnology industry’s exceptional growth, there is unprecedented competition for qualified and experienced CEO candidates. Furthermore, in the deep tech arena, biotech investors and boards may not have the luxury of selecting from a pool of CEOs who have “been there, done that.” Join us for a fireside chat to hear insights and what it takes to be a successful biotech CEO.
Given the biotechnology industry’s exceptional growth, there is unprecedented competition for qualified and experienced CEO candidates. Furthermore, in the deep tech arena, biotech investors and boards may not have the luxury of selecting from a pool of CEOs who have “been there, done that.”
Join us for an inspirational discussion to hear insights and what it takes to be a successful biotech CEO. Seats are limited for this closed-door event, so please register your interest here. We will confirm your attendance closer to the event.
Date: 10 January 2023, Tuesday
Time: 5:00pm - 7:00pm (Singapore Time / UTC +8)
Location: 32 Carpenter Street, Singapore 095511
Speaker's Profile:
Andrew Bruce, CEO, MediSix Therapeutics
As the CEO of MediSix Therapeutics based from our headquarters in Singapore, Andrew Bruce leads a strong and growing team in further developing the work of Professor Dario Campana in T-cell engineering. Andrew is an accomplished professional with more than 36 years in the pharmaceutical industry.
He has gained broad experience across a range of functions from sales and marketing to supply chain and logistics, medical affairs, therapy area strategy and corporate development. Andrew has held leadership positions within the pharmaceutical, biotech and medical consulting industries, in addition to commercial and strategy roles, including founding and subsequent sale of a global specialist medical consulting leader.
He moved to Singapore in March 2021. Andrew gained his BSc at the University of Bradford.
Moderator's Profile:Dr Lim Jui, CEO, SGInnovate
As CEO of SGInnovate, Dr Lim Jui has overall leadership of the organisation that is committed to helping entrepreneurial scientists build and scale Deep Tech startups. At SGInnovate, Jui and his team work closely with a wide range of partners and co-investors to back this unique group of founders, who are looking to solve global challenges with their research-based solutions. This is done through equity-based investments, access to the Deep Tech ecosystem and talent network, as well as by providing business-building support.
While he trained in medicine, Jui had spent most of his professional life in the business of science and innovation. He was Director of Investments, Bio*One Capital; CEO of Merlin MD, a medical device company; Executive Director of the Medical Engineering Research and Commercialisation Initiative (MERCI) at the National University of Singapore (NUS); and Programme Director of the Singapore-Stanford Biodesign Programme (SSB), a joint venture between the Agency for Science, Technology and Research (A*STAR), the Singapore Economic Development Board (EDB) and Stanford University. Before joining SGInnovate, Jui was CEO of NTUitive, the innovation and enterprise company of the Nanyang Technological University (NTU).
He currently serves on the advisory boards of IPOS International, the business arm of the Intellectual Property Office of Singapore (IPOS), and several startup companies. He was previously a board member of the Building and Construction Authority (BCA) in Singapore.
Jui received his Bachelor of Arts (BA, Biological Sciences and East Asian Studies) and Doctor of Medicine (MD) at Columbia University. He then obtained his Master of Medicine (Anaesthesiology and Surgical Intensive Care) from NUS. He remains a registered medical practitioner today.
